OncoRes Medical

High-Level Overview

OncoRes Medical is a Perth-based medical device company founded in 2016, developing an intraoperative imaging technology that combines optical coherence tomography (OCT) and micro-elastography to provide surgeons with real-time, microscale images of tissue microstructure.[1][2][3] The Quantitative Micro-Elastography (QME) handheld probe translates a surgeon's sense of touch into high-resolution 3D images overlaid with AI-powered analysis, primarily targeting breast-conserving surgery to detect residual cancer cells, reduce reoperation rates, and improve surgical accuracy.[2][3][4] It serves surgeons and patients in oncology, particularly breast cancer, addressing the problem of incomplete tumor removal during operations, where up to 20-30% of cases require repeat surgery due to positive margins.[1][4] Backed by $6 million from the Medical Research Commercialisation Fund (MRCF) and Australian government programs like BioMedTech Horizons, OncoRes has gained recognition as a top MedTech startup in APAC (2020) and Australia (2025), showing strong growth through awards and collaborations with the University of Western Australia, Harry Perkins Institute, and Western Australian health experts.[1][3][4]

Origin Story

OncoRes Medical emerged from a collaboration between breast cancer surgeon Christobel Saunders and biomedical engineer Brendan Kennedy, who sought to digitize the surgeon's tactile feedback to solve the high reoperation rates in breast-conserving surgery.[1][3] Founded in 2016 in Perth, Western Australia, the company was sparked by Saunders' clinical insights into the limitations of current intraoperative assessment tools, leading to the invention of QME technology.[1][2] Early traction came via partnerships with the University of Western Australia, Harry Perkins Institute of Medical Research, and Western Australian Department of Health surgeons and pathologists, securing patent protection and $6 million in non-dilutive funding from the MRCF—supported by the Australian Federal Government and superannuation funds like AustralianSuper and HOSTPLUS.[1][3] Under CEO Katharine Giles, these pivotal moments positioned OncoRes for clinical development, with the technology advancing toward real-world applications in tissue microstructure assessment.[1]

Core Differentiators

• Novel QME Technology: Combines OCT (measures light back-scatter for high-resolution 3D imaging) with micro-elastography (assesses tissue stiffness) into Quantitative Micro-Elastography, delivering histology-comparable images in real-time without needing excised samples.[2][3]
• Handheld Probe with AI Integration: Portable intraoperative tool provides surgeons instant feedback on tumor margins via AI-driven analysis, enhancing precision in cancer detection and reducing complications like repeat surgeries.[3][4]
• Patent-Protected and Clinically Validated: Developed through collaborations with top researchers and surgeons, offering superior micro-architecture visualization over traditional methods like frozen section pathology.[1][2]
• Ease of Use and Speed: Real-time imaging at the surgical site improves workflow, with recognition as a top Australian MedTech innovator for its seamless integration into operating rooms.[4]

Role in the Broader Tech Landscape

OncoRes Medical rides the wave of AI-enhanced intraoperative imaging and precision oncology, where trends like real-time tissue analytics address rising demands for minimally invasive cancer surgeries amid global breast cancer incidence growth.[4] Timing aligns with advancements in OCT and elastography, accelerated by post-pandemic focus on efficient medtech; Australian government backing via MRFF and BioMedTech Horizons exemplifies national pushes for medtech commercialization.[3] Market forces favoring OncoRes include aging populations driving oncology needs, shortages in pathology staffing, and a shift to value-based care that rewards reduced reoperations—potentially saving healthcare systems millions.[1][4] By enabling clearer margins in breast-conserving procedures (preserving ~70% of cases), OncoRes influences the ecosystem, inspiring similar tools for other cancers and boosting Australia's medtech hub status in APAC.[1][5]

Quick Take & Future Outlook

OncoRes Medical is poised for clinical trials and regulatory milestones, leveraging its MRCF funding and awards to launch the QME probe commercially within 2-3 years, expanding from breast to other solid-tumor surgeries.[3][4] Trends like AI-surgical integration and portable diagnostics will propel growth, with potential partnerships for global scaling amid a medtech market projected to hit $600B by 2028. Its influence may evolve from niche innovator to ecosystem leader, redefining intraoperative decisions and tying back to its core mission: turning surgeons' intuition into actionable, life-improving precision.[1][2][4]